News|Videos|October 13, 2026

Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC

Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.

The FDA's expanding embrace of new approach methodologies (NAMs) is forcing pharmaceutical manufacturing and quality teams to rethink how preclinical and CMC data will be generated, validated, and used. Richard Jaenisch, speaking with PharmTech associate editorial director Christopher Cole, lays out both the promise and the unresolved questions that come with it.

Related to this article

AAPS PharmSci 360 2026: Roller-Compacted Formulations
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.